vosoritide

targets

all catalysts(0)

nothing on the calendar yet

News(8)

• 5 biotechs braving the commercial waters with product launches
  A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
  biospace · 13d ago
• Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
  Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
  biopharma_dive · 26d ago
• Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
  Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…
  biospace · 28d ago
• BioMarin acquires experimental drug for rare bone disorder in $275M deal
  The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
  biopharma_dive · 1mo ago
• BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
  BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.
  fiercebiotech · 1mo ago
• Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
  Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…
  biopharma_dive · 1mo ago
• BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
  BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.
  biospace · 1mo ago
• BioMarin drug acquired in buyout misses goal in rare disease study
  Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
  biopharma_dive · 4mo ago